Clinical TrialsThe ACUITY trial confirmed safety with no adverse events imbalance, supporting the continued development of OCS-05.
Market PotentialThe price objective for Oculis stock has been raised due to higher risk-adjusted value of OCS-05, reflecting increased confidence in its market potential.
Regulatory MilestonesFDA has granted IND clearance for OCS-05, enabling the initiation of registrational development in acute optic neuritis, while exploring additional formulations for other chronic conditions.